N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes

Circulation. 2004 Nov 16;110(20):3206-12. doi: 10.1161/01.CIR.0000147611.92021.2B. Epub 2004 Nov 8.

Abstract

Background: Elevated baseline levels of B-type natriuretic peptide (BNP) and the N-terminal fragments of its prohormone, N-terminal-pro-BNP (NT-proBNP), have been associated with adverse long-term outcome in patients with acute coronary syndromes, whereas the prognostic implications of serial NT-proBNP measurements have not been investigated to date.

Methods and results: NT-proBNP, troponin T, and C-reactive protein were measured at baseline and at 48 and 72 hours in 1791 patients with non-ST-elevation acute coronary syndromes. Death and myocardial infarction were recorded during 30 days of follow-up. After adjustment for independent predictors of cardiac risk, baseline NT-proBNP levels >250 ng/L were associated with higher event rates (adjusted OR, 3.7; 95% CI, 2.3 to 5.7; P<0.001). In troponin T-negative patients, NT-proBNP identified a subgroup of high-risk patients (OR, 5.9; 95% CI, 2.6 to 13.3; P<0.001). The risk in those patients (7.2%) did not significantly differ from that in troponin T-positive patients (9.8%; P=0.25). Importantly, clinical stabilization without refractory ischemia was associated with a rapid (as soon as 48 hours after onset of symptoms) and significant (48 hours; -24%; 72 hours, -49%; both P<0.001) decline in NT-proBNP levels. In patients with high NT-proBNP baseline levels, lack of a rapid decline in NT-proBNP levels (< or =250 ng/L) was linked to an adverse short-term prognosis (OR, 33.7; 95% CI, 8.2 to 138.8; P<0.001). In patients with low NT-proBNP baseline levels, a rise in NT-proBNP levels over 72 hours to >250 ng/L was also linked to an adverse 30-day prognosis (OR, 24.0; 95% CI, 8.4 to 68.5; P<0.001).

Conclusions: Neurohumoral activation as evidenced by NT-proBNP appears as a unifying feature that is independent of other biochemical markers (myocardial necrosis, inflammation) and is a powerful and independent determinant of the short-term cardiac risk in patients with acute coronary syndromes. Whether serial measurements of NT-proBNP in patients with ACS may be used to more rapidly identify patients suitable for early discharge or more intensive therapy deserves future prospective studies.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use
  • Aspirin / administration & dosage
  • Aspirin / therapeutic use
  • Biomarkers
  • C-Reactive Protein / analysis
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Heparin / therapeutic use
  • Humans
  • Incidence
  • Myocardial Infarction / mortality
  • Myocardial Ischemia / blood*
  • Myocardial Ischemia / classification
  • Myocardial Ischemia / drug therapy
  • Myocardial Ischemia / mortality
  • Natriuretic Peptide, Brain
  • Nerve Tissue Proteins / blood*
  • Peptide Fragments / blood*
  • Predictive Value of Tests
  • Risk
  • Risk Assessment
  • Syndrome
  • Tirofiban
  • Troponin T / blood
  • Tyrosine / administration & dosage
  • Tyrosine / analogs & derivatives*
  • Tyrosine / therapeutic use

Substances

  • Anticoagulants
  • Biomarkers
  • Nerve Tissue Proteins
  • Peptide Fragments
  • Troponin T
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Tyrosine
  • Heparin
  • C-Reactive Protein
  • Tirofiban
  • Aspirin